FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
CO-57 | NXT007 PROPHYLAXIS IN PEOPLE WITH HEMOPHILIA A WITH OR WITHOUT FACTOR VIII INHIBITORS: COMBINED ANALYSIS OF TWO PHASE I/II MULTIPLE-ASCENDING-DOSE STUDIES M.E. Mancuso1|2, M. Shima3, J.M. Staber4, Y.C. Chen5, F.J. López-Jaime6, M.C. Shen7, G. Ventriglia8, M. Takeyama9, C. Schmitt8, Y.S. Park10, A. Kiialainen8, N. Mizuno11, M. Niggli8, T. Miyake11, D. Matino12, T. Saito11, V. Jiménez-Yuste13, R. Kobayashi11, D. Hart14, K. Nogami15 | 1Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milano, Italy; 2Center for Thrombosis and Hemorrhagic Diseases, IRCCS Humanitas Research Hospital, Rozzano, Milano, Italy; 3Thrombosis and Hemostasis Research Center, Nara Medical University, Kashihara, Nara, Japan; 4Stead Family Department of Pediatrics, Carver College of Medicine, University of Iowa, Iowa City, USA; 5Hemophilia Care and Research Center, Tri-Service General Hospital, National Defense Medical University, Taipei, Taiwan; 6Servicio de Hematología, Hospital Universitario Regional de Málaga / Instituto de Investigación Biomédica de Málaga (IBIMA), Málaga, Spain; 7Department of Internal Medicine, Changhua Christian Hospital, Changhua, Taiwan; 8F. Hoffmann-La Roche Ltd, Basel, Switzerland; 9Division of Hemophilia, National Hospital Organization, Osaka National Hospital, Osaka, Japan; 10Department of Pediatrics, Kyung Hee University Hospital at Gangdong, Seoul, South Korea; 11Chugai Pharmaceutical Co., Ltd, Tokyo, Japan; 12McMaster University, Hamilton, Ontario, Canada; 13La Paz University Hospital-IdiPAZ, Autónoma University, Madrid, Spain; 14Roche Products Ltd, Welwyn Garden City, UK; 15Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan
46PDF: 17 -
CO-10 | APPLICATIONS OF ARTIFICIAL INTELLIGENCE IN HEMOPHILIA MANAGEMENT: INNOVATIONS AND FUTURE PERSPECTIVES A. Ierardi, M. Leotta, A. Strangio, S. Prejanò, R.C. Santoro | UO Hemophilia, Hemostasis and Thrombosis. Azienda Ospedaliero Universitaria Renato Dulbecco, Catanzaro, Italy
90PDF: 17 -
CO-56 | EVALUATING AN AI MODEL’S HEMATOLOGY CONSULTATION PERFORMANCE FOR HOSPITALIZED PATIENTS WITH BLEEDING DISORDERS G. Sottilotta1, F. Misiti2, G. Praticò1, D. Megalizzi1, F. Luise3 | 1UOSD Microcitemie - Emostasi e Trombosi. Grande Ospedale Metropolitano di Reggio Calabria, Italy; 2Associazione Emofilici di Reggio Calabria, Italy; 3Laboratorio Analisi. Grande Ospedale Metropolitano di Reggio Calabria, Italy
46PDF: 17 -
PO14 | Searching for safer rescue immunosuppressive therapy protocols in acquired hemophilia A: two case reports G. Quintavalle1, I.M. Tassoni1, B.M. Roccon1, G. Lucchini2, F. Magalini2, M. Zardo2, R. Rossi3, C. Cattabiani3, A. Tagliaferri1, A. Coppola1 | 1SSD Centro HUB Emofilia e MEC; 2UOS Medicina Interna e Reumatologia; 3UO Diagnostica Ematochimica, Azienda Ospedaliero Universitaria, Parma, Italy
554PDF: 20 -
PO005 | EXTENDED ANTICOAGULATION WITH DOACS IN PATIENTS AFFECTED BY HEMATOLOGIC MALIGNANCIES AND VENOUS THROMBOEMBOLISM: DOES LOW DOSE FIT ALL? M. Biglietto, S. Sorella, L.V. Cappelli, B. Mandelli, D. Kasmi, E. Baldacci, A. Chistolini | Sapienza University of Roma, Italy
17PDF: 8 -
PO118 | VARIATION OF EGFR IN PATIENT IN DOACS THERAPY S. Vivolo, C. Gagliardi, A. Ciampa | U.O.S.D. Centro Emostasi Aorn S. G. Moscati Avellino, Italy
19PDF: 10 -
BEST-06 | OPTIMIZING LABORATORY MONITORING OF EFANESOCTOCOG ALFA: IMPACT OF APTT REAGENTS AND CHROMOGENIC ASSAYS ON DIAGNOSTIC ACCURACY A. Strangio, A. Ierardi, M. Leotta, L.C. Elia, M. Falbo, C. Condina, G. Procopio, R.C. Santoro | Hemophilia Hemostasis and Thrombosis Unit, Azienda Ospedaliero Universitaria Renato Dulbecco, Catanzaro, Italy
86PDF: 16 -
CO-37 | STEW-EFA STUDY: MULTICENTER EVALUATION OF ONE-STAGE AND CHROMOGENIC ASSAYS FOR EFANESOCTOCOG ALFA MEASUREMENT ON STAGO AND WERFEN PLATFORMS A.C. Molinari1, M. Marchetti2, A. Catalano3, L. Contino4, R. De Cristofaro5, A.B. Federici6, T. Martini7, I. Quaglia8, R. Rossi9, R. Santoro10, A. Tripodi11, A. Valpreda12 | 1Regional Reference Centre for Hemorrhagic Diseases, Department of Hemato-Oncology, IRCCS Istituto Giannina Gaslini, Genova, Italy; 2Department of Immunohematology and Transfusion Medicine, ASST Papa Giovanni XXIII, Bergamo, Italy; 3Società per la Promozione dell'educazione Medica (S.P.E.Me), Italy; 4Hemostasis and Thrombosis Unit, AOU SS Antonio e Biagio e C Arrigo, Alessandria, Italy; 5Dipartimento di Medicina e Chirurgia Traslazionale, Facoltà di Medicina e Chirurgia "Agostino Gemelli," Università Cattolica S. Cuore, Roma, Italy - Servizio Malattie Emorragiche e Trombotiche, Fondazione Policlinico Universitario "A. Gemelli" Istituto di Ricerca e Cura a Carattere Scientifico, Roma, Italy; 6School of Medicine and Surgery, University of Milan-Bicocca, Milano, Italy; 7Hemophilia Centre, Immune-Hematology and Transfusion Medicine, University Hospital “Città della Salute e della Scienza", Torino, Italy; 8Center for Thrombosis and Hemorrhagic Diseases, IRCCS Humanitas Research Hospital Rozzano, Milan, Italy; 9Laboratory of Clinical Chemistry and Hematology, University Hospital of Parma, Italy; 10Hemophilia, Hemostasis, and Thrombosis Unit, Azienda Ospedaliero Universitaria Dulbecco, Catanzaro, Italy; 11IRCCS Ca' Granda Maggiore Hospital Foundation and Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milano, Italy; 12Central Laboratory Baldi and Riberi, AOU Città della Salute e della Scienza, Turin, Italy, reference laboratory of the Regional Center for Hemostasis and Thrombosis.
39PDF: 15 -
PO130 | HEMORRHAGIC AND THROMBOTIC COMPLICATIONS DURING DOACS TREATMENT: THE IMPORTANCE OF A REGULAR AND PROLONGED FOLLOW-UP D. Barcellona1|2, A. Mameli2, S. Cornacchini2, P. Schirru2, L. Fenu2, V. Casu2, F. Marongiu1|2 | 1University of Cagliari, Italy; 2Haemostasis and Thrombosis Unit, Azienda Ospedaliero-Universitaria di Cagliari, Italy
32PDF: 6 -
CO-09 | THE POSSIBLE ROLE OF THE PSYCHOLOGIST IN THE MANAGEMENT OF PATIENTS WITH CONGENITAL BLEEDING DISORDERS: THE EXPERIENCE OF A SINGLE HEMOPHILIA CENTER D. Meneghini1, E. Tosi1, B. Pernice2, L. Del Piccolo2, M. Bodini1, A.C. Giuffrida1 | 1Transfusion Medicine Dep., Integrated University Hospital, Verona, Italy; 2Dep. of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Italy
89PDF: 13 -
PO49 | Use of emicizumab in two patients with acquired hemophilia A: a new therapeutic approach S. Sorella, J. Micozzi, E. Baldacci, M. Biglietto, R. Mormile, A. Chistolini, R. Ciciani, L. Torrieri, N. Zhdanovskaya, M. Lorenzon, A. Delli Paoli, S. Ligia, C. Santoro | Hematology, Department of Translational and Precision Medicine, Policlinico Umberto I, Sapienza University of Roma, Italy
665PDF: 25 -
PO069 | PERIOPERATIVE CHALLENGES IN ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA DURING CAPLACIZUMAB TREATMENT J. Agnelli Giacchello1, P. Sciancalepore1, N.F. Trincheri2, L. Contino1, M. Ladetto3, R.M. Santi1 | 1SSD Emostasi e trombosi e malattie rare; 2SC Laboratorio Analisi; 3SCDU Ematologia, AOU SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
22PDF: 8 -
PO41 | VENOUS THROMBOEMBOLISM IN PERIPHERAL BLOOD STEM CELL COLLECTION. A SINGLE CENTER EXPERIENCE P. Holly1, J. Hudecek1, J. Chudej1, L. Valekova1, I. Plamenova1, E. Flochova1, R. Simonova1, J. Sokol1, J. Stasko1, M. Pietrzykova1|2, E. Vescecikova2 | 1Department of Hematology and Transfusion Medicine, University Hospital in Martin, Martin, Slovakia; 2National Transfusion Service, Martin, Slovakia
520PDF: 103 -
PO12 | Characterisation and real word clinical data of HEM006, a newly formulated intranasal spray desmopressin (DDAVP) to address a global treatment gap G. De Giorgi1, A. Gringeri2, R. Franceschini1, A. Koganti3 | 1Hemorare Srl, Italy; 2Fondazione Charta, Milan, Italy; 3Quenya LLC, USA
580PDF: 12 -
PO002 | VENOUS THROMBOEMBOLISM IN PATIENTS WITH FACTOR VII DEFICIENCY: A CASE SERIES AND REVIEW OF THE LITERATURE BM. Roccon1, MI. Tassoni1, G. Quintavalle1, F. Riccardi1, A. Matichecchia1, GF. Rivolta1, M. Lombardi3, R. Rossi2, A. Benegiamo2, A. Tagliaferri1, A. Coppola1 | 1SSD Centro Hub Emofilia e Malattie Emorragiche Congenite, Azienda Ospedaliero-Universitaria di Parma, Italy; 2Lab. di Coagulazione, UOC Diagnostica Ematochimica, Azienda Ospedaliero-Universitaria di Parma, Italy; 3Centro Emostasi, UOC Medicina Interna ad indirizzo angiologico e coagulativo, Azienda Ospedaliero-Universitaria di Parma, Italy
26PDF: 11 -
CO-20 | REAL-WORLD EXPERIENCE ON THE MANAGEMENT OF MILD HEAD INJURY IN A COHORT OF CHILDREN WITH HEMOPHILIA A WITH AND WITHOUT INHIBITORS TREATED WITH EMICIZUMAB B. Pollio1, B. Borsellino1|2, T. Martini1 | 1Haemophilia Centre, Immune-Haematology and Transfusion Medicine, University Hospital “Città della Salute e della Scienza”, Torino, Italy; 2Department of Biomedicine and Prevention, PhD in Immunology, Molecular Medicine and Applied Biotechnology, University of Rome Tor Vergata, Roma, Italy
36PDF: 15 -
The evolving landscape of gene therapy for congenital severe hemophilia: a 2024 state of the art
2089PDF: 359SUPPLEMENTARY MATERIAL: 218 -
PO114 | A CASE OF ACQUIRED HEMOPHILIA AFTER TAVI AND CORONARY ANGIOPLASTY IN PATIENT WITH ATRIAL FIBRILLATION AND MULTIPLES CARDIOVASCULAR RISK FACTORS – THE ART AND SCIENCE OF THERAPEUTIC CONFLICT M.M. Poggi1, C. Tamburini2, M. Littera2, M. Mazzetti2 | 1SOC Medicina 1, Nuovo Ospedale Prato, Prato, Italy; 2SOD Medicina Interna Interdisciplinare, Azienda Ospedaliera Universitaria Careggi, Firenze, Italy
26PDF: 7 -
PO39 | Bleeding events in Von Willebrand disease type 1 yearly treatable with desmopressin A. Gringeri1,2, P.M. Mannucci3, M. Gringeri4, G. Castaman5, F. Peyvandi3,6 | 1Fondazione Charta, Milan; 2Centro di Sanità Solidale, Lucca; 3Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and Fondazione Luigi Villa, Milan; 4Department of Medical Biotechnologies and Translational Medicine, Postgraduate School of Clinical Pharmacology and Toxicology, University of Milan; 5Centre for Bleeding Disorders and Coagulation, Careggi University Hospital, Firenze; 6Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Italy
645PDF: 23 -
CO31 | Immune system profiling in FVIII-treated and emicizumab-treated pediatric HA patients A. Cottonaro1, S. Akula1, B. Pollio2, I. Ricca2, T. Martini2, J. Agnelli Giacchello3, P. Sciancalepore3, R. Santi3, A. Follenzi1,3, S. Merlin1 | 1Università del Piemonte Orientale, Health Sciences, Novara; 2A.O. Città della Salute e della Scienza, SIMT Immunohematology and Transfusion Medicine Service, Diagnostic Department, Torino; 3Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
644PDF: 15 -
PO129 | CLINICAL BENEFIT OF RECOMBINANT ADAMTS13 IN CTTP ASSOCIATED WITH HOMOZYGOUS PD173G MUTATION AND UNDETECTABLE ACTIVITY M. Sacco1, S. Lancellotti1, M. Basso1, R. De Cristofaro1|2 | 1Servizio Malattie Emorragiche e Trombotiche, Fondazione Policlinico Universitario Gemelli IRCCS, Roma, Italy; 2Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica S. Cuore, Roma, Italy
22PDF: 8 -
CO-78 | REAL-WORLD MANAGEMENT OF ACQUIRED HEMOPHILIA A: FOCUS ON RECOMBINANT PORCINE FVIII AS FIRST-LINE HEMOSTATIC TREATMENT AND LONG-TERM OUTCOMES M. Leotta, A. Strangio, A. Ierardi, R.C. Santoro | Hemophilia, Hemostasis and Thrombosis Centre, Azienda Ospedaliero Universitaria Renato Dulbecco, Catanzaro, Italy
44PDF: 16 -
CO-08 | IMPLEMENTING A HUB-AND-SPOKE MODEL FOR HEMOPHILIA DIAGNOSIS AND CARE IN BURKINA FASO THROUGH TRAINING OF “HEALTH ASSISTANTS” C. Gorio1, E. Kafando2, A. Buzzi3 | 1Oncohematology Unit ASST Spedali Civili Brescia, Italy; 2Centre Hospitalier Universitaire Charles de Gaulle, Italy; 3Fondazione Paracelso ETS, Milano, Italy
83PDF: 15 -
PO36 | EXTENDED DURATION REDUCED DOSE ANTICOAGULATION IN CANCER-ASSOCIATED THROMBOSIS: A REAL-WORLD COHORT WITH LONG TERM FOLLOW UP A. Bhide1, I. Welding1, O. Ogunbiyi1, S. Hawkins2, E. Greenlay1, N. Prasannan1, J. Westwood1, M. Thomas1 | 1Department of Clinical Haematology, University College London Hospital, London; 2Data Clinic, University College London, UK; A. Bhide and I. Welding joint First Authors
492PDF: 116 -
CO066 | COAGULOPATHY IN CAR-T CELL-TREATED PATIENTS WITH LYMPHOPROLIFERATIVE DISORDERS: A RETROSPECTIVE, SINGLE-CENTER OBSERVATIONAL STUDY I. Santo1, R. Morganti2, G. Leoni3, G. Tancredi3, L. Contino4, S. Galimberti3, R.M. Santi4, E. Orciuolo5 | 1Azienda Toscana Nord Ovest, Versilia Hospital, Italy; 2Hematology Division AOUP, Pisa, Italy; 3University of Pisa, Hematology Pisa, Italy; 4Azienda Ospedaliera Universitaria Alessandria, Italy; 5Azienda Ospedaliera Universitaria Pisana, Hematology Pisa, Italy
31PDF: 9 -
CO-19 | A CASE OF LOSS OF EFFICACY OF EMICIZUMAB AFTER 6 YEARS OF REGULAR USE M.R. Fasulo1, I. Quaglia1, A. Colombo1, C. Lodigiani1, M.E. Mancuso1|2 | 1Center for Thrombosis and Hemorrhagic Diseases, IRCCS Humanitas Research Hospital, Rozzano, Milano, Italy; 2Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milano, Italy
45PDF: 16 -
PO80 | Heparin-induced thrombocytopenia: a monocentric experience with danaparoid L. D’Innocenzo, S. Sorrentino, M. De Siati, A. Ferretti, E. De Candia | Unit of Haemostasis and Thrombosis Diseases, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Roma, Italy
702PDF: 13
